Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares stood at 0.39 million during the last session, with the company’s beta value hitting 2.96. At the close of trading, the stock’s price was $16.79, to imply an increase of 4.55% or $0.73 in intraday trading. The ARCT share’s 52-week high remains $45.00, putting it -168.02% down since that peak but still an impressive 14.83% since price per share fell to its 52-week low of $14.30.
Analysts have given a consensus recommendation of Buy for Arcturus Therapeutics Holdings Inc (ARCT), translating to a mean rating of 1.00. Of 6 analyst(s) looking at the stock, 1 analyst(s) give ARCT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.49.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
After registering a 4.55% upside in the last session, Arcturus Therapeutics Holdings Inc (ARCT) has traded red over the past five days. The 5-day price performance for the stock is -5.51%, and -0.30% over 30 days. With these gigs, the year-to-date price performance is -1.06%.
The extremes give us $10.58 and $10.58 for target low and target high price respectively. As such, ARCT has been trading 36.99% off suggested target high and 36.99% from its likely low.
Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts
The rating firms project that company’s revenue will grow 2.53% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 44.64M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 56.24M.Earnings reports from the last fiscal year show that sales brought in 33.99M and 38.01M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 31.34% before jumping 47.95% in the following quarter.
ARCT Dividends
Arcturus Therapeutics Holdings Inc has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is BLACKROCK INC. with 2.65 million shares, or about 9.8262% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64.52 million.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Arcturus Therapeutics Holdings Inc (ARCT) shares. Going by data provided on Oct 31, 2024 , Federated Hermes Kaufmann Fund holds roughly 2.44 shares. This is just over 8.99% of the total shares, with a market valuation of $40.9 million. Data from the same date shows that the other fund manager holds a little less at 2.2, or 8.11% of the shares, all valued at about 36.9 million.
